Data from a prospective, open-label, head-to-head clinical trial for migraine presented at the 18th Congress of the International Headache Society in Vancouver (Canada, 7–10 September 2017) have demonstrated more favorable tolerability profile for Botox® (onabotulinumtoxinA) compared with Topamax® (topiramate).
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.
